Answers are grounded in this paper and cite their sources.
Introduction Treatment with luspatercept may improve transfusion requirements in transfusion‐dependent thalassemia (TDT), but the improved erythroid maturation in the bone marrow influences body iron distribution. Case Report We report on sequential organ iron measurements in a TDT patient under luspatercept treatment. Despite a decline in transfusion requirement and ferritin, we observed a redistribution of body iron stores from spleen and bone marrow to the liver, increasing liver iron concentration (LIC). Conclusion Luspatercept treatment affects the informative value of ferritin and LIC in the assessment of total body iron stores, which should be considered in the management of iron chelation therapy.
No takes yet. Share an insight, caveat, or question.
Grosse et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: